Enhanced expression and HIV- 1 inhition of chimeric tRNALys3-Ribozymes under dual U6 snRNA and tRNA promoters

Zongli Chang, Shawn Westaway, Shirley Li, John A. Zaia, John J. Rossi, Lisa J. Scherer

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We previously demonstrated that chimeric tRNALys3-ribozymes targeting the primer binding site of HIV produced virions with reduced infectivity. To further enhance the anti-HIV efficiency of these ribozymes by increasing their level of transcription, we designed several tRNALys3 promoter variants and compared their expression levels from the internal tRNALys3 promoters and also from an exogenous human U6 snRNA promoter. The dual U6/tRNA promoter constructs gave rise to much higher levels of expression than constructs that used only an internal tRNA promoter. The most abundant expression is produced when a U6 promoter drives a chimeric tRNALys3-ribozyme containing a mutation in the tRNA B box. As detected by fluorescent in situ hybridization, transcripts from a construct with the tRNA promoter alone localized strictly to the cytoplasm, whereas transcripts from dual U6/tRNA promoter were present in both the cytoplasm and the nucleus. Inhibition of HIV-1 correlates well with expression levels of the chimeric constructs. The results presented demonstrate that U6 and tRNA promoters can be placed in tandem for high-level expression of small RNA therapeutic transcripts.

Original languageEnglish (US)
Pages (from-to)481-489
Number of pages9
JournalMolecular Therapy
Volume6
Issue number4
DOIs
StatePublished - Oct 1 2002

Fingerprint

Catalytic RNA
Transfer RNA
HIV-1
Cytoplasm
HIV
Fluorescence In Situ Hybridization
Virion
U6 small nuclear RNA
Binding Sites
RNA
Mutation

Keywords

  • Gene therapy
  • Human immunodeficiency virus
  • Primer binding site
  • Promoter
  • Ribozyme
  • RNA polymerase III
  • Subcellular localization
  • tRNA
  • tRNA
  • U6 small nuclear RNA (U6 snRNA)

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Enhanced expression and HIV- 1 inhition of chimeric tRNALys3-Ribozymes under dual U6 snRNA and tRNA promoters. / Chang, Zongli; Westaway, Shawn; Li, Shirley; Zaia, John A.; Rossi, John J.; Scherer, Lisa J.

In: Molecular Therapy, Vol. 6, No. 4, 01.10.2002, p. 481-489.

Research output: Contribution to journalArticle

Chang, Zongli ; Westaway, Shawn ; Li, Shirley ; Zaia, John A. ; Rossi, John J. ; Scherer, Lisa J. / Enhanced expression and HIV- 1 inhition of chimeric tRNALys3-Ribozymes under dual U6 snRNA and tRNA promoters. In: Molecular Therapy. 2002 ; Vol. 6, No. 4. pp. 481-489.
@article{db669eeda01d42e7a29ce4dbaac4da66,
title = "Enhanced expression and HIV- 1 inhition of chimeric tRNALys3-Ribozymes under dual U6 snRNA and tRNA promoters",
abstract = "We previously demonstrated that chimeric tRNALys3-ribozymes targeting the primer binding site of HIV produced virions with reduced infectivity. To further enhance the anti-HIV efficiency of these ribozymes by increasing their level of transcription, we designed several tRNALys3 promoter variants and compared their expression levels from the internal tRNALys3 promoters and also from an exogenous human U6 snRNA promoter. The dual U6/tRNA promoter constructs gave rise to much higher levels of expression than constructs that used only an internal tRNA promoter. The most abundant expression is produced when a U6 promoter drives a chimeric tRNALys3-ribozyme containing a mutation in the tRNA B box. As detected by fluorescent in situ hybridization, transcripts from a construct with the tRNA promoter alone localized strictly to the cytoplasm, whereas transcripts from dual U6/tRNA promoter were present in both the cytoplasm and the nucleus. Inhibition of HIV-1 correlates well with expression levels of the chimeric constructs. The results presented demonstrate that U6 and tRNA promoters can be placed in tandem for high-level expression of small RNA therapeutic transcripts.",
keywords = "Gene therapy, Human immunodeficiency virus, Primer binding site, Promoter, Ribozyme, RNA polymerase III, Subcellular localization, tRNA, tRNA, U6 small nuclear RNA (U6 snRNA)",
author = "Zongli Chang and Shawn Westaway and Shirley Li and Zaia, {John A.} and Rossi, {John J.} and Scherer, {Lisa J.}",
year = "2002",
month = "10",
day = "1",
doi = "10.1006/mthe.2002.0696",
language = "English (US)",
volume = "6",
pages = "481--489",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Enhanced expression and HIV- 1 inhition of chimeric tRNALys3-Ribozymes under dual U6 snRNA and tRNA promoters

AU - Chang, Zongli

AU - Westaway, Shawn

AU - Li, Shirley

AU - Zaia, John A.

AU - Rossi, John J.

AU - Scherer, Lisa J.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - We previously demonstrated that chimeric tRNALys3-ribozymes targeting the primer binding site of HIV produced virions with reduced infectivity. To further enhance the anti-HIV efficiency of these ribozymes by increasing their level of transcription, we designed several tRNALys3 promoter variants and compared their expression levels from the internal tRNALys3 promoters and also from an exogenous human U6 snRNA promoter. The dual U6/tRNA promoter constructs gave rise to much higher levels of expression than constructs that used only an internal tRNA promoter. The most abundant expression is produced when a U6 promoter drives a chimeric tRNALys3-ribozyme containing a mutation in the tRNA B box. As detected by fluorescent in situ hybridization, transcripts from a construct with the tRNA promoter alone localized strictly to the cytoplasm, whereas transcripts from dual U6/tRNA promoter were present in both the cytoplasm and the nucleus. Inhibition of HIV-1 correlates well with expression levels of the chimeric constructs. The results presented demonstrate that U6 and tRNA promoters can be placed in tandem for high-level expression of small RNA therapeutic transcripts.

AB - We previously demonstrated that chimeric tRNALys3-ribozymes targeting the primer binding site of HIV produced virions with reduced infectivity. To further enhance the anti-HIV efficiency of these ribozymes by increasing their level of transcription, we designed several tRNALys3 promoter variants and compared their expression levels from the internal tRNALys3 promoters and also from an exogenous human U6 snRNA promoter. The dual U6/tRNA promoter constructs gave rise to much higher levels of expression than constructs that used only an internal tRNA promoter. The most abundant expression is produced when a U6 promoter drives a chimeric tRNALys3-ribozyme containing a mutation in the tRNA B box. As detected by fluorescent in situ hybridization, transcripts from a construct with the tRNA promoter alone localized strictly to the cytoplasm, whereas transcripts from dual U6/tRNA promoter were present in both the cytoplasm and the nucleus. Inhibition of HIV-1 correlates well with expression levels of the chimeric constructs. The results presented demonstrate that U6 and tRNA promoters can be placed in tandem for high-level expression of small RNA therapeutic transcripts.

KW - Gene therapy

KW - Human immunodeficiency virus

KW - Primer binding site

KW - Promoter

KW - Ribozyme

KW - RNA polymerase III

KW - Subcellular localization

KW - tRNA

KW - tRNA

KW - U6 small nuclear RNA (U6 snRNA)

UR - http://www.scopus.com/inward/record.url?scp=0036800369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036800369&partnerID=8YFLogxK

U2 - 10.1006/mthe.2002.0696

DO - 10.1006/mthe.2002.0696

M3 - Article

C2 - 12377189

AN - SCOPUS:0036800369

VL - 6

SP - 481

EP - 489

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -